TOVX

Theriva Biologics, Inc. (TOVX) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Theriva Biologics is a clinical-stage biopharmaceutical company focused on oncology, specifically developing oncolytic adenoviruses (lead candidate VCN-01) for pancreatic cancer and retinoblastoma. The company also maintains legacy gastrointestinal assets (SYN-004, SYN-020) but is prioritizing oncology. As of November 7, 2025, the company had approximately 33.7 million shares of common stock outstanding.

Key Financial Metrics

Note: Revenue is $0 as the company has no commercial products. Net loss per share improved significantly in 2025 due to a reverse stock split and share issuances increasing the weighted average shares outstanding.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased to $4.4 million in Q3 2025 from $7.9 million in Q3 2024. This reduction is primarily due to the absence of goodwill and in-process R&D (IPR&D) impairment charges recorded in Q3 2024 ($1.5M and $1.3M respectively).
• Contingent Consideration: A significant non-cash charge of $9.8 million was recorded in the first nine months of 2025 related to the fair value adjustment of contingent consideration. This increase was driven by the successful achievement of primary survival and safety endpoints in the VIRAGE Phase 2b clinical trial for VCN-01.
• Balance Sheet: Cash decreased from $11.6 million at year-end 2024 to $7.5 million at Q3 2025. However, total liabilities increased significantly due to the reclassification of a $6 million milestone payment to Grifols (related to the VIRAGE trial success) from contingent consideration to accrued expenses.
• Workforce Reduction: On September 30, 2025, the company implemented a workforce reduction of approximately 32% (7 employees) to extend its cash runway, incurring an estimated $520,000 charge.

Guidance, Outlook, and Risks

• Going Concern: The filing includes a "substantial doubt" regarding the company's ability to continue as a going concern without additional capital. Management estimates current cash (including subsequent financing) will fund operations into the first quarter of 2027.
• Subsequent Financing: Following the quarter-end, the company raised approximately $10.5 million in net proceeds through October 2025 via an ATM offering ($6.1M) and a warrant inducement exercise ($4.4M), bringing total cash to approximately $15.5 million as of early November 2025.
• Clinical Outlook: The company is preparing for pivotal Phase 3 trials of VCN-01 in metastatic pancreatic ductal adenocarcinoma (mPDAC) and retinoblastoma. The VIRAGE Phase 2b trial met its primary endpoints, showing improved overall survival and progression-free survival.
• Risks: Key risks include the inability to secure additional funding for Phase 3 trials, potential delays due to U.S. federal government shutdowns affecting FDA/SEC operations, and the obligation to pay a deferred $5 million milestone to Grifols upon securing a licensing or business development transaction.

Investor Verification Checklist

• Cash Runway: Verify the sustainability of the $15.5 million cash position (as of Nov 2025) against the projected burn rate and the specific costs of the planned Phase 3 trials.
• Contingent Liability: Confirm the terms of the deferred $5 million milestone payment to Grifols and the likelihood of triggering this payment via a future partnership.
• Regulatory Timeline: Assess the impact of the U.S. government shutdown on the timing of upcoming FDA meetings for VCN-01 Phase 3 design.
• Dilution: Review the impact of the recent warrant inducement (issuing 16.2 million new warrants) and ATM sales on existing shareholder dilution.
• Asset Strategy: Monitor progress on out-licensing or partnering for the legacy GI assets (SYN-004, SYN-020) to generate non-dilutive revenue.